JP2013523686A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523686A5
JP2013523686A5 JP2013501816A JP2013501816A JP2013523686A5 JP 2013523686 A5 JP2013523686 A5 JP 2013523686A5 JP 2013501816 A JP2013501816 A JP 2013501816A JP 2013501816 A JP2013501816 A JP 2013501816A JP 2013523686 A5 JP2013523686 A5 JP 2013523686A5
Authority
JP
Japan
Prior art keywords
vaccine according
polypeptide
vaccine
antigen
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523686A (ja
JP5942296B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/054866 external-priority patent/WO2011120994A1/en
Publication of JP2013523686A publication Critical patent/JP2013523686A/ja
Publication of JP2013523686A5 publication Critical patent/JP2013523686A5/ja
Application granted granted Critical
Publication of JP5942296B2 publication Critical patent/JP5942296B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501816A 2010-03-29 2011-03-29 少なくとも1つのcxxcモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用 Expired - Fee Related JP5942296B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305317 2010-03-29
EP10305317.9 2010-03-29
PCT/EP2011/054866 WO2011120994A1 (en) 2010-03-29 2011-03-29 Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof

Publications (3)

Publication Number Publication Date
JP2013523686A JP2013523686A (ja) 2013-06-17
JP2013523686A5 true JP2013523686A5 (cg-RX-API-DMAC7.html) 2014-05-15
JP5942296B2 JP5942296B2 (ja) 2016-06-29

Family

ID=42312972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501816A Expired - Fee Related JP5942296B2 (ja) 2010-03-29 2011-03-29 少なくとも1つのcxxcモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用

Country Status (12)

Country Link
US (1) US9801927B2 (cg-RX-API-DMAC7.html)
EP (2) EP2552476B1 (cg-RX-API-DMAC7.html)
JP (1) JP5942296B2 (cg-RX-API-DMAC7.html)
KR (1) KR101866301B1 (cg-RX-API-DMAC7.html)
CN (1) CN103002909B (cg-RX-API-DMAC7.html)
AR (1) AR081809A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012024872B1 (cg-RX-API-DMAC7.html)
CA (1) CA2792174C (cg-RX-API-DMAC7.html)
ES (1) ES2619077T3 (cg-RX-API-DMAC7.html)
SG (1) SG183977A1 (cg-RX-API-DMAC7.html)
UY (1) UY33297A (cg-RX-API-DMAC7.html)
WO (1) WO2011120994A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249202B2 (en) 2006-08-11 2016-02-02 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
ES2637812T3 (es) 2008-02-14 2017-10-17 Life Sciences Research Partners Vzw Inmunoterapia dirigida a patógenos intracelulares
CA2715484C (en) 2008-02-14 2017-04-11 Life Sciences Research Partners Vzw Suppression of immune responses to viral vectors
EP2249864B1 (en) * 2008-02-14 2016-05-04 Life Sciences Research Partners VZW Strategies to prevent and/or treat immune responses to soluble allofactors
EP2249855B1 (en) * 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic peptides and their use in transplantation
EP2247306B1 (en) 2008-02-14 2018-04-18 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
US10023847B2 (en) 2010-11-25 2018-07-17 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
JP2014212722A (ja) * 2013-04-24 2014-11-17 学校法人加計学園 八面体構造を有するb型肝炎ウイルス様粒子結晶
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) * 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
US11787849B2 (en) 2015-09-25 2023-10-17 Imcyse Sa Methods and compounds for eliminating immune responses to therapeutic agents
US11485768B2 (en) 2016-04-19 2022-11-01 Imcyse Sa Immunogenic CD1d binding peptides
CU24596B1 (es) 2017-03-09 2022-05-11 Imcyse Sa Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes
EP4144752A1 (en) * 2021-09-02 2023-03-08 Sorbonne Universite Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165469A (en) * 1988-01-13 2000-12-26 University Of Virginia Recombinant Entamoeba histolytica lectin subunit peptides and reagents specific for members of the 170 kD subunit multigene family
DE60041042D1 (de) * 1999-03-12 2009-01-22 Aventis Pasteur Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
IN2008CN05409A (cg-RX-API-DMAC7.html) 2002-07-18 2015-10-02 Cytos Biotechnology Ag
US7943396B2 (en) * 2004-06-22 2011-05-17 The Regents Of The University Of California Peptide-coated nanoparticles with graded shell compositions
EP1763693B1 (de) 2004-07-02 2009-11-18 Schölly Fiberoptic GmbH Vorrichtung und verwendung der vorrichtung zur aufnahme und verarbeitung eines bildes
WO2006026746A2 (en) 2004-08-31 2006-03-09 The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to separate and expand antigen-specific t cells
GB0426641D0 (en) * 2004-12-03 2005-01-05 Bioactive Protein Delivery The Protein delivery system
AU2007242572B2 (en) 2006-04-13 2011-11-24 Midatech Limited Nanoparticles containing three various ligands for providing immune responses against infectious agents
US9439959B2 (en) * 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
US9249202B2 (en) * 2006-08-11 2016-02-02 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
EP2199301A1 (en) * 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof

Similar Documents

Publication Publication Date Title
JP2013523686A5 (cg-RX-API-DMAC7.html)
Medhi et al. Nanoparticle-based strategies to combat COVID-19
Gupta et al. Platforms, advances, and technical challenges in virus-like particles-based vaccines
Jackman et al. Rupture of lipid vesicles by a broad-spectrum antiviral peptide: influence of vesicle size
US12472244B2 (en) Immunogenic compositions and uses thereof
Yan et al. The application of virus-like particles as vaccines and biological vehicles
Yadav et al. Virus-like particle-based L2 vaccines against HPVs: where are we today?
Prange Host factors involved in hepatitis B virus maturation, assembly, and egress
SG131116A1 (en) Functional influenza virus-like particles (vlps)
Singh et al. Insights from nanotechnology in COVID-19: prevention, detection, therapy and immunomodulation
EP2361930A3 (en) Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
JP2016519933A5 (cg-RX-API-DMAC7.html)
Zhou et al. Vaccine strategies for human papillomavirus-associated head and neck cancers
JP2010011868A5 (cg-RX-API-DMAC7.html)
MX375379B (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
JP2020506690A5 (cg-RX-API-DMAC7.html)
JP2010522208A5 (cg-RX-API-DMAC7.html)
CN106008716A (zh) 呼吸道合胞病毒抗原组合物和方法
JP2019536426A5 (cg-RX-API-DMAC7.html)
JP2016539641A5 (cg-RX-API-DMAC7.html)
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
JP2010538619A5 (cg-RX-API-DMAC7.html)
Chhikara et al. Viral infection mitigations using advanced nanomaterials and tools: lessons from SARS-CoV-2 for future prospective interventions